Cartesian Therapeutics (RNAC) Assets (2015 - 2026)
Cartesian Therapeutics (RNAC) posted quarterly Assets of $288.4 million for Q1 2026, down 29.51% year-over-year from $409.1 million in Q1 2025, and down 2.71% quarter-over-quarter from $296.4 million in Q4 2025.
Cartesian Therapeutics (RNAC) Assets (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has reported Assets for 12 consecutive years, with $288.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets fell 29.51% year-over-year to $288.4 million; the TTM figure through Mar 2026 stood at $288.4 million (down 29.51% YoY), while the FY2025 annual figure was $296.4 million, down 31.86% from the prior year.
- Assets fell to $288.4 million in Q1 2026 per RNAC's latest filing, from $296.4 million in the prior quarter.
- Across five years, Assets topped out at $455.3 million in Q3 2024 and bottomed at $106.0 million in Q3 2023.
- Historically, Assets has averaged $276.6 million across 5 years, with a median of $296.4 million in 2025.
- Annual changes were most pronounced in 2023 — Assets slumped 40.52% — and 2024, when it soared 329.41%.
- Cartesian Therapeutics' Assets stood at $165.9 million in 2022, then surged by 83.89% to $305.0 million in 2023, then jumped by 42.61% to $435.0 million in 2024, then sank by 31.86% to $296.4 million in 2025, then retreated by 2.71% to $288.4 million in 2026.
- Business Quant data shows RNAC's Assets at $288.4 million in Q1 2026, $296.4 million in Q4 2025, and $372.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Cartesian Therapeutics | 265.54 Mn | 265.54 Mn | - | 318.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 318.63 Mn |
| Mar 31, 2026 | 288.39 Mn |
| Dec 31, 2025 | 296.41 Mn |
| Sep 30, 2025 | 372.68 Mn |
| Jun 30, 2025 | 388.89 Mn |
| Mar 31, 2025 | 409.13 Mn |
| Dec 31, 2024 | 435.02 Mn |
| Sep 30, 2024 | 455.32 Mn |
| Jun 30, 2024 | 347.74 Mn |
| Mar 31, 2024 | 325.21 Mn |
| Dec 31, 2023 | 305.05 Mn |
| Sep 30, 2023 | 106.03 Mn |
| Jun 30, 2023 | 139.51 Mn |
| Mar 31, 2023 | 155.69 Mn |
| Dec 31, 2022 | 165.89 Mn |
| Sep 30, 2022 | 178.27 Mn |
| Jun 30, 2022 | 188.07 Mn |
| Mar 31, 2022 | 145.70 Mn |
| Dec 31, 2021 | 159.88 Mn |
| Sep 30, 2021 | 167.16 Mn |